Efe Eworuke

Dr. Efe Eworuke

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Journal of Critical Care
Verified
Journal Article
Closed access
EEEfe Eworuke
Efe Eworuke
JMJacqueline M. Major
Jacqueline M. Major
LMLydia I. Gilbert McClain
Lydia I. Gilbert McClain

1 January 2021 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
VSVeronica Sansing-Foster
Veronica Sansing-Foster
NHNicole Haug
Nicole Haug
AMAndrew Mosholder
Andrew Mosholder
NCNoelle M. Cocoros
Noelle M. Cocoros
MBMarie Bradley
Marie Bradley
EEEfe Eworuke
Efe Eworuke

4 December 2020 in Regional Anesthesia & Pain Medicine
Verified
Journal Article
Closed access
PDF file
EEEfe Eworuke
Efe Eworuke
LCLeah Crisafi
Leah Crisafi
JLJiemin Liao
Jiemin Liao
SASandia Akhtar
Sandia Akhtar
MCMartha Van Clief
Martha Van Clief
DGDavid J Graham
David J Graham
Background Epidural corticosteroid injections (ESIs) are widely performed and have an unquantified risk of serious spinal adverse events (SSAEs). We sought to determine the rate of SSAEs following ESI and to compare the rates by spinal level, injection approach and corticosteroid formulation. Methods We included patients enrolled in Medicare parts A and B who had an ESI between 1 January 2009 and 30 September 2015. We identified potential cases as patients with spine-related diagnoses within 3 days after the first eligible ESI. Event categorization as probable, possible or non-case was based on review of medical records. The rates of probable and possible cases were expressed per 1 000 000 patients overall, and by spinal level, injection approach and corticosteroid formulation. A score test was used to compare these rates. Results We identified 1 355 957 eligible ESIs during the study period. Of the 110 potential cases, 43 were selected for medical record review and 11 were categorized as probable, yielding a rate of 8.1 per 1 000 000 patients (95% CI 4.5 to 14.5). Risk of SSAEs was statistically higher with cervical/thoracic injections (29.4, 95% CI 12.5 to 68.8) compared with lumbar/sacral injections (5.1, 95% CI 2.3 to 11.0) (p value 0.001). Event rates for lumbar/sacral non-transforaminal injections was 8.8 (95% CI 4.0 to 19.1). Event rates for particulate (7.5, 95% CI 3.9 to 14.2) and non-particulate formulations (13.1, 95% CI 3.6 to 47.9) appeared similar (p value 0.47). Conclusion Between 2009 and 2015, rates of SSAEs following ESI in the Medicare population were low. Patients receiving cervical/thoracic ESIs were at higher risk of SSAE than those receiving lumbar/sacral ESIs. Event rates were similar for each corticosteroid formulation.

4 February 2021 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
EEEfe Eworuke
Efe Eworuke
NHNicole Haug
Nicole Haug
MBMarie Bradley
Marie Bradley
ACAustin Cosgrove
Austin Cosgrove
TZTancy Zhang
Tancy Zhang
STSengwee Toh
Sengwee Toh
Background: European studies reported an increased risk of nonmelanoma skin cancer associated with hydrochlorothiazide (HCTZ)-containing products. We examined the risks of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) associated with HCTZ compared with angiotensin-converting enzyme inhibitors (ACEIs) in a US population. Methods: We conducted a retrospective cohort study in the US Food and Drug Administration’s Sentinel System. From the date of HCTZ or ACEI dispensing, patients were followed until a SCC or BCC diagnosis requiring excision or topical chemotherapy treatment on or within 30 days after the diagnosis date or a censoring event. Using Cox proportional hazards regression models, we estimated the hazard ratios (HRs), overall and separately by age, sex, and race. We also examined site- and age-adjusted incidence rate ratios (IRRs) by cumulative HCTZ dose within the matched cohort. Results: Among 5.2 million propensity–score matched HCTZ and ACEI users, the incidence rate (per 1000 person-years) of BCC was 2.78 and 2.82, respectively, and 1.66 and 1.60 for SCC. Overall, there was no difference in risk between HCTZ and ACEIs for BCC (HR = 0.99, 95% confidence interval [CI] = 0.97 to 1.00), but there was an increased risk for SCC (HR = 1.04, 95% CI = 1.02 to 1.06). HCTZ use was associated with higher risks of BCC (HR = 1.09, 95% CI = 1.07 to 1.11) and SCC (HR = 1.15, 95% CI = 1.12 to 1.17) among Caucasians. Cumulative HCTZ dose of 50 000 mg or more was associated with an increased risk of SCC in the overall population (IRR = 1.19, 95% CI = 1.05 to 1.35) and among Caucasians (IRR = 1.27, 95% CI = 1.10 to 1.47). Conclusions: Among Caucasians, we identified small increased risks of BCC and SCC with HCTZ compared with ACEI. Appropriate risk mitigation strategies should be taken while using HCTZ.

1 December 2016 in Papillomavirus Research
Verified
Journal Article
Open access
YCYoonyoung Choi
Yoonyoung Choi
EEEfe Eworuke
Efe Eworuke
RSRichard Segal
Richard Segal
To identify factors that explain differences in HPV vaccination rates for male and female adolescents and to determine self-reported barriers by parents affecting vaccination decisions. The sample included adolescents 13-17 years old with a vaccination record documented in the 2012 and 2013 National Immunization Survey-Teen dataset. A logistic regression model was developed with 13 socio-demographic factors and survey year, along with significant interaction pairs with gender. Subjects included 20,355 and 18,350 adolescent boys and girls, respectively. About half of the females (56%) received at least one dose of HPV vaccine, compared to 28% of males. Several factors differed between males and females, including higher vaccination rates among non-Hispanic Black males and lower vaccination rates for non-Hispanic Black females compared to Whites; and a stronger association with health care provider recommendation among males. The most common parental reasons for not vaccinating their children included 'not recommended by a health care provider' for males (24%), and 'unnecessary' for females (18%). We found a significant gender interaction with several socio-demographic variables in predicting vaccination uptake. These gender differences may be partially an artifact of timing, because male vaccination became routine approximately five years after female vaccination.

17 April 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
EEEfe Eworuke
Efe Eworuke
MSMayura Shinde
Mayura Shinde
LHLaura Hou
Laura Hou
MPMichael J Paterson
Michael J Paterson
PJPeter Bjødstrup Jensen
Peter Bjødstrup Jensen
MBMarie C Bradley
Marie C Bradley
Objectives To examine valsartan, losartan and irbesartan usage and switching patterns in the USA, UK, Canada and Denmark before and after July 2018, when the first Angiotensin-Receptor-Blocker (ARB) (valsartan) was recalled. Design Retrospective cohort study. Setting USA, Canadian administrative healthcare data, Danish National Prescription Registry and UK primary care electronic health records. Participants Patients aged 18 years and older between January 2014 and December 2020. Intervention Valsartan, losartan and irbesartan. Main outcome Monthly percentages of individual ARB episodes, new users and switches to another ARB, ACE inhibitors (ACEI) or calcium channel blockers containing products. Results We identified 10.8, 3.2, 1.8 and 1.2 million ARB users in the USA, UK, Canada and Denmark, respectively. Overall proportions of valsartan, losartan and irbesartan use were 18.4%, 67.9% and 5.2% in the USA; 3.1%, 48.3% and 10.2% in the UK, 16.3%, 11.4% and 18.3% in Canada, 1%, 93.5% and 0.6% in Denmark. In July 2018, we observed an immediate steep decline in the proportion of valsartan use in the USA and Canada. A similar trend was observed in Denmark; however, the decline was only minimal. We observed no change in trends of ARB use in the UK. Accompanying the valsartan decline was an increase in switching to other ARBs in the USA, Canada and Denmark. There was a small increase in switching to ACEI relative to the valsartan-to-other-ARBs switch. We also observed increased switching from other affected ARBs, losartan and irbesartan, to other ARBs throughout 2019, in the USA and Canada, although the usage trends in the USA remained unchanged. Conclusion The first recall notice for valsartan resulted in substantial decline in usage due to increased switching to other ARBs. Subsequent notices for losartan and irbesartan were also associated with increased switching around the time of the recall, however, overall usage trends remained unchanged.